MAP2K7 and metastatic melanoma: The researchers further noted that trametinib, a specific inhibitor of the MAP2K/MEK-MAPK1/3 pathway, which has been FDA-approved for the treatment of metastatic melanoma harboring the BRAF V600E mutation, significantly reduced breast cancer bone metastasis and extended survival in mice with wild-type ULK1 breast cancer xenografts.